Oracle Introduces Oracle Health Sciences Clinical Development Center Version 3.1
Oracle
today announced the availability of Oracle Health Sciences Clinical Development Center 3.1, a centralized solution for integrating, managing, and analyzing clinical trial information.
The release provides new integration, increased automation, and expanded data standardization to accelerate processing of clinical trial data from multiple sources in a variety of formats and increase user productivity from capture through submission.
Oracle Health Sciences Clinical Development Center 3.1 features automated data load and new execution triggers to increase the timeliness and accuracy of data analysis. The system now automatically reruns routines and programs against the most recent data and notifies users of data and study changes as they occur. The system can also be personalized to notify users of specific events that require their attention.
New governance capabilities allow for the creation of validated libraries to drive standardization, control and reuse of data models, macros, and programs across studies.
Version 3.1 also features a pre-built integration with Oracle Health Sciences InForm GTM electronic data capture (EDC) solution, as well as enhanced support for Medidata Rave clinical data management and EDC platform, automating the set up of Medidata Rave studies and data loading to save time and reduce potential for error. Oracle Health Sciences Clinical Development Center 3.1 now also supports the use of Interactive SAS for program development, and integrates with Oracle’s Siebel Clinical Trial Management System to help auto load study metadata.
The latest version also supports the management of data from studies in multiple languages.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
